Regulus Therapeutics Inc (RGLS)
2.26
+0.04
(+1.80%)
USD |
NASDAQ |
Apr 25, 13:28
Regulus Therapeutics Enterprise Value: 122.90M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 24, 2024 | 122.90M |
April 23, 2024 | 125.52M |
April 22, 2024 | 121.60M |
April 19, 2024 | 117.01M |
April 18, 2024 | 122.90M |
April 17, 2024 | 130.76M |
April 16, 2024 | 145.16M |
April 15, 2024 | 159.57M |
April 12, 2024 | 160.87M |
April 11, 2024 | 159.57M |
April 10, 2024 | 149.09M |
April 09, 2024 | 154.33M |
April 08, 2024 | 152.36M |
April 05, 2024 | 143.85M |
April 04, 2024 | 142.54M |
April 03, 2024 | 148.44M |
April 02, 2024 | 155.64M |
April 01, 2024 | 160.87M |
March 28, 2024 | 166.11M |
March 27, 2024 | 166.11M |
March 26, 2024 | 163.82M |
March 25, 2024 | 162.18M |
March 22, 2024 | 153.35M |
March 21, 2024 | 159.57M |
March 20, 2024 | 141.24M |
Date | Value |
---|---|
March 19, 2024 | 133.71M |
March 18, 2024 | 132.07M |
March 15, 2024 | 115.70M |
March 14, 2024 | 137.63M |
March 13, 2024 | 27.04M |
March 12, 2024 | 25.61M |
March 11, 2024 | 5.662M |
March 08, 2024 | 5.682M |
March 07, 2024 | 6.288M |
March 06, 2024 | 7.906M |
March 05, 2024 | 7.502M |
March 04, 2024 | 7.704M |
March 01, 2024 | 7.704M |
February 29, 2024 | 7.299M |
February 28, 2024 | 7.704M |
February 27, 2024 | 8.007M |
February 26, 2024 | 6.288M |
February 23, 2024 | 7.097M |
February 22, 2024 | 8.513M |
February 21, 2024 | 8.108M |
February 20, 2024 | 8.816M |
February 16, 2024 | 8.513M |
February 15, 2024 | 7.502M |
February 14, 2024 | 7.502M |
February 13, 2024 | 9.119M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-26.85M
Minimum
Jan 24 2022
166.11M
Maximum
Mar 27 2024
13.07M
Average
6.052M
Median
Enterprise Value Benchmarks
ACADIA Pharmaceuticals Inc | 2.295B |
ADMA Biologics Inc | 1.554B |
FibroGen Inc | -24.46M |
Protara Therapeutics Inc | -33.34M |
Amylyx Pharmaceuticals Inc | -243.93M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -8.061M |
Total Expenses (Quarterly) | 8.30M |
EPS Diluted (Quarterly) | -0.39 |
Earnings Yield | -69.91% |
Normalized Earnings Yield | -243.36 |